Healthcare venture capitalists are no fans of the U.S. Food and Drug Administration and the regulatory challenges the agency poses for medical startups and device companies.
They blame many of the problems besetting healthcare investing squarely on the agency as delays caused by reviewers push investor pay day further out.
But at the MedTechInvesting Conference in Minneapolis on Monday, moderator Bill Harrington, managing partner at Osage University Partners, half jokingly cautioned that there will be no whining on the matter.
To read the full, original article click on this link: Advice from a VC to startups: Speak no evil about the FDA
